Merck and Moderna’s longstanding 50/50 profit-sharing collaboration on the personalized mRNA cancer vaccine intismeran autogene, reinforced by statistically significant Phase 3 INTerpath-001 data released August 19, 2026, that drove Moderna shares up as much as 177% and Merck higher by 12%, continues to deliver aligned economics without requiring corporate combination. Merck’s recent bolt-on acquisitions, including Terns Pharmaceuticals for $6.7 billion in March 2026, reflect its strategy of targeted portfolio diversification ahead of Keytruda patent expiration rather than large-scale integration with a smaller partner whose market capitalization remains roughly one-tenth its own. Trader consensus at 98.9% for no announced merger or acquisition by year-end prices in the absence of deal rumors, mismatched scale, and the durability of the existing equal-cost, equal-profit structure. Tail risks include an unforeseen strategic pivot if additional late-stage vaccine readouts materially alter growth trajectories or competitive dynamics, though such a development would face substantial regulatory and shareholder hurdles before resolution.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated1% chance
NEW
NEW
Dec 31, 2026
1% chance
NEW
NEW
Dec 31, 2026
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna’s longstanding 50/50 profit-sharing collaboration on the personalized mRNA cancer vaccine intismeran autogene, reinforced by statistically significant Phase 3 INTerpath-001 data released August 19, 2026, that drove Moderna shares up as much as 177% and Merck higher by 12%, continues to deliver aligned economics without requiring corporate combination. Merck’s recent bolt-on acquisitions, including Terns Pharmaceuticals for $6.7 billion in March 2026, reflect its strategy of targeted portfolio diversification ahead of Keytruda patent expiration rather than large-scale integration with a smaller partner whose market capitalization remains roughly one-tenth its own. Trader consensus at 98.9% for no announced merger or acquisition by year-end prices in the absence of deal rumors, mismatched scale, and the durability of the existing equal-cost, equal-profit structure. Tail risks include an unforeseen strategic pivot if additional late-stage vaccine readouts materially alter growth trajectories or competitive dynamics, though such a development would face substantial regulatory and shareholder hurdles before resolution.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Market Opened: Aug 19, 2026, 3:58 PM ET
Volume
$425End Date
Dec 31, 2026Market Opened
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna’s longstanding 50/50 profit-sharing collaboration on the personalized mRNA cancer vaccine intismeran autogene, reinforced by statistically significant Phase 3 INTerpath-001 data released August 19, 2026, that drove Moderna shares up as much as 177% and Merck higher by 12%, continues to deliver aligned economics without requiring corporate combination. Merck’s recent bolt-on acquisitions, including Terns Pharmaceuticals for $6.7 billion in March 2026, reflect its strategy of targeted portfolio diversification ahead of Keytruda patent expiration rather than large-scale integration with a smaller partner whose market capitalization remains roughly one-tenth its own. Trader consensus at 98.9% for no announced merger or acquisition by year-end prices in the absence of deal rumors, mismatched scale, and the durability of the existing equal-cost, equal-profit structure. Tail risks include an unforeseen strategic pivot if additional late-stage vaccine readouts materially alter growth trajectories or competitive dynamics, though such a development would face substantial regulatory and shareholder hurdles before resolution.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Volume
$425End Date
Dec 31, 2026Market Opened
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...Merck and Moderna’s longstanding 50/50 profit-sharing collaboration on the personalized mRNA cancer vaccine intismeran autogene, reinforced by statistically significant Phase 3 INTerpath-001 data released August 19, 2026, that drove Moderna shares up as much as 177% and Merck higher by 12%, continues to deliver aligned economics without requiring corporate combination. Merck’s recent bolt-on acquisitions, including Terns Pharmaceuticals for $6.7 billion in March 2026, reflect its strategy of targeted portfolio diversification ahead of Keytruda patent expiration rather than large-scale integration with a smaller partner whose market capitalization remains roughly one-tenth its own. Trader consensus at 98.9% for no announced merger or acquisition by year-end prices in the absence of deal rumors, mismatched scale, and the durability of the existing equal-cost, equal-profit structure. Tail risks include an unforeseen strategic pivot if additional late-stage vaccine readouts materially alter growth trajectories or competitive dynamics, though such a development would face substantial regulatory and shareholder hurdles before resolution.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions